ADVERTISEMENT
Executive Changes
UK liquids specialist Rosemont Pharmaceuticals has named industry veteran Alok Sonig as its new CEO, as the firm continues to set its sights on the US market. Meanwhile, Rosemont has also appointed Gavin Wood as chief financial officer.
Hikma has initiated a leadership transition, with CEO Riad Mishlawi stepping down after just two years in the role, as margin pressure in its core Injectables business and operational delays weigh on performance.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
As Alvotech continues to reorganize its senior team with the promotion of chief scientific officer Joseph McClellan to chief operating officer, multiple other firms – including Hikma, Hyloris, CNX and Cingulate – have also announced executive updates.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.